Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677486 | 1.00 | SMYD3 (0.32) | SMYD3KDM1AMAOB | |
| SCHEMBL23489031 | 1.00 | SMYD3 (0.32) | SMYD3KDM1AMAOB | |
| SCHEMBL10198836 | 0.86 | — | — | |
| SCHEMBL20687474 | 0.86 | — | — | |
| SCHEMBL4153538 | 0.86 | — | — | |
| SCHEMBL12219599 | 0.85 | — | — | |
| Cyclohexylamine SCHEMBL6867516 | 0.83 | ALDH1A1 (0.36) | — | |
| SCHEMBL27115503 | 0.82 | SMYD3 (0.31) | SMYD3KDM1AMAOB | |
| SCHEMBL29332587 | 0.78 | GNAI3 (0.30) | — | |
| Cyclohexylamine SCHEMBL8692790 | 0.78 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20220411396-A1 | TRIOXOLANE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-12-29 | — | — | US | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-3623398-A1 | MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012026452-A1 | TRIAZINE RING-CONTAINING POLYMER AND MEMBRANE-FORMING COMPOSITION CONTAINING THE SAME | 日産化学工業株式会社 (JP) | 2012-03-01 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411396-A1 | TRIOXOLANE AGENTS | ABCB4, SLC10A1, SLC10A2 | SMYD3 3600/4885KDM1A 4175/4885MAOB 4222/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | SMYD3 4111/4885KDM1A 1088/4885MAOB 2300/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | SMYD3 2481/4885KDM1A 807/4885MAOB 1764/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | SMYD3 3068/4885KDM1A 3865/4885MAOB 3546/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | SMYD3 1144/4885KDM1A 2593/4885MAOB 3347/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | SMYD3 2112/4885KDM1A 4648/4885MAOB 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.